Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EBITDA | -66.06M | -52.39M | -60.56M | -27.33M | 8.42M |
Net Income | -64.44M | -45.39M | -60.36M | 3.55M | 8.42M |
Balance Sheet | |||||
Total Assets | 172.50M | 179.53M | 100.84M | 141.51M | 4.72M |
Cash, Cash Equivalents and Short-Term Investments | 170.57M | 176.50M | 99.81M | 13.79K | 4.72M |
Total Debt | 0.00 | 0.00 | 0.00 | 355.60K | 0.00 |
Total Liabilities | 21.09M | 19.51M | 21.29M | 14.82M | 39.00K |
Stockholders Equity | 138.20M | 146.81M | 59.33M | -32.06M | 4.68M |
Cash Flow | |||||
Free Cash Flow | -34.27M | -28.15M | -23.05M | -13.07M | -1.10M |
Operating Cash Flow | -34.16M | -28.08M | -15.05M | -1.07M | -1.10M |
Investing Cash Flow | -117.00K | -5.08M | -8.00M | -12.00M | -139.38M |
Financing Cash Flow | 115.03M | 109.84M | 121.29M | 355.60K | 141.21M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
52 Neutral | $117.19M | ― | -52.76% | ― | -70.31% | -11.68% | |
51 Neutral | $7.55B | 0.39 | -61.90% | 2.32% | 17.14% | 1.55% | |
49 Neutral | $104.04M | ― | -61.14% | ― | -100.00% | -24.28% | |
43 Neutral | $64.97M | ― | -62.34% | ― | ― | 86.65% | |
36 Underperform | $113.61M | ― | -34.87% | ― | ― | 15.09% | |
35 Underperform | $98.78M | ― | -54.64% | ― | ― | 1.27% | |
30 Underperform | $126.38M | ― | -744.59% | ― | ― | 27.65% |
On February 24, 2025, Zura Bio announced its participation in the Leerink Partners Global Healthcare Conference scheduled for March 11, 2025. The company’s senior leadership will engage in a fireside chat and host investor meetings, reflecting its proactive approach to engaging with stakeholders and potentially enhancing its market visibility.